Suppr超能文献

去γ-羧基凝血酶原影响边缘肝功能 HCC 患者的生存和根治性治疗:ACROS1402。

Des-gamma-carboxy prothrombin affects the survival of HCC patients with marginal liver function and curative treatment: ACRoS1402.

机构信息

Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.

Department of Surgery, School of Medicine, Keio University, Tokyo, Japan.

出版信息

J Cancer Res Clin Oncol. 2020 Nov;146(11):2949-2956. doi: 10.1007/s00432-020-03270-2. Epub 2020 May 27.

Abstract

PURPOSE

Considering the initial treatment of hepatocellular carcinoma (HCC), the best prognostic index for Child-Pugh classes B and C (CP-BC) patients has not been yet established. This study aimed to elucidate the risk factors for disease-free survival (DFS) and overall survival (OS) in multicenter patients with a poor liver functional reserve after curative treatment.

METHODS

Between April 2000 and April 2014, 212 CP-BC patients who received treatment in five high-volume centers in Japan were included in this study. CP-B and C patients were 206 and 6, respectively. Cox proportional hazard regression analyses for DFS and OS were performed to estimate the risk factors.

RESULTS

The mean observation time was 1132 days. Mean Child-Pugh score and indocyanine green retention rate at 15 min were 7.5 and 31.5%, respectively. Histological chronic hepatitis and liver cirrhosis were observed in 20% and 74% patients, respectively. In the multivariate analysis, the risk factors for DFS were des-gamma-carboxy prothrombin (DCP) [hazard ratio (HR), 1.6; P = 0.012] and treatment without liver transplantation. Moreover, DCP was identified as an independent risk factor for OS (HR, 1.7; P = 0.01). Tumor size, number, tumor thrombus, Milan criteria, liver cirrhosis, and treatment without liver transplantation were not identified as risk factors for OS. The 5-year OS in patients with high serum DCP levels (< 90 mAU/mL) was significantly better than that in those with low serum DCP levels (P = 0.003).

CONCLUSIONS

Serum DCP value before treatment predicted both DFS and OS in CP-BC patients with HCC.

摘要

目的

考虑到肝细胞癌(HCC)的初始治疗,CP-BC 患者的最佳预后指数尚未确定。本研究旨在阐明在具有较差肝功能储备的多中心患者中,根治性治疗后无疾病生存(DFS)和总生存(OS)的风险因素。

方法

2000 年 4 月至 2014 年 4 月期间,在日本 5 个大容量中心接受治疗的 212 例 CP-BC 患者纳入本研究。CP-B 和 C 患者分别为 206 例和 6 例。对 DFS 和 OS 进行 Cox 比例风险回归分析以评估风险因素。

结果

中位观察时间为 1132 天。平均 Child-Pugh 评分和 15 分钟时的吲哚菁绿滞留率分别为 7.5 和 31.5%。20%的患者存在组织学慢性肝炎,74%的患者存在肝硬化。多变量分析显示,DFS 的风险因素为去γ-羧基凝血酶原(DCP)[风险比(HR),1.6;P=0.012]和未行肝移植治疗。此外,DCP 是 OS 的独立危险因素(HR,1.7;P=0.01)。肿瘤大小、数量、肿瘤栓子、米兰标准、肝硬化和未行肝移植治疗均不是 OS 的危险因素。高血清 DCP 水平(<90 mAU/mL)患者的 5 年 OS 明显优于低血清 DCP 水平患者(P=0.003)。

结论

治疗前血清 DCP 值可预测 CP-BC 合并 HCC 患者的 DFS 和 OS。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验